Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Novartis Stories

2014-03-25 08:32:50

BASEL, Switzerland, March 25, 2014 /PRNewswire/ -- Syngenta today announced the successful issue of CHF 750 million in Swiss domestic bonds. This issue comprises a CHF 350 million Swiss domestic bond with maturity date in November 2019, a CHF 250 million Swiss domestic bond with maturity date in November 2024 and a CHF 150 million Swiss domestic bond with maturity date in November 2029. John Ramsay, CFO, said: "We have taken advantage of current favorable...

2014-03-24 12:30:48

BASEL, Switzerland, March 24, 2014 /PRNewswire/ -- Syngenta announced today the successful issue of EUR 750 million in Eurobonds. This issue comprises a EUR 500 million Eurobond with maturity date in November 2021 and a EUR 250 million Eurobond with maturity date in October 2017. John Ramsay, CFO, said: "We have taken advantage of current favorable market conditions in order to further enhance our debt maturity profile. These bond issues are part of our...

2014-03-21 16:23:03

- First-in-class medicine approved for CIU, a burdensome skin condition that can cause hives, severe itch, and swelling that can last many months and years EAST HANOVER, N.J., March 21, 2014 /PRNewswire/ -- Novartis today announced that the US Food and Drug Administration (FDA) approved Xolair(®) (omalizumab) for the treatment of chronic idiopathic urticaria (CIU), a form of chronic hives. The new use is for patients 12 years of age and older who remain symptomatic despite treatment with...

2014-03-19 04:20:42

BASEL, Switzerland, March 19, 2014 /PRNewswire/ -- Syngenta today announced that its 2013 Annual Report is now available at www.syngenta.com/ar2013. The 2013 Annual Report consists of the following documents: -- Annual Review, incorporating the Corporate Responsibility Report -- Financial Report -- Corporate Governance and Compensation Report All documents are in English and German except for the Financial Report, which is published in English only. Printed copies of these...

2014-03-18 12:32:29

LONDON, March 18, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Adult Vaccines Market, Company Adult Vaccines Sales, Country Adult Vaccines - Worldwide Analysis World Adult Vaccines Market - Market OverviewFor much of the 20th century, vaccines were a pharmaceutical success story largely associated with children. Aggressive immunization programs eradicated Polio and Smallpox among developed nations and nearly eliminated Mumps, Pertussis, Measles,...

2014-03-12 08:31:21

ATLANTA, March 12, 2014 /PRNewswire/ -- Avion Pharmaceuticals, a specialty pharmaceutical company, recently announced the promotion of Mike Sullivan to the position of President. Sullivan joined Avion Pharmaceuticals in 2011 as Vice President of Sales and Marketing. Tapped for his expertise in building corporate "start-up" pharmaceutical organizations, he has been instrumental in the commercial development, infrastructure and successful launch of Avion over the past three years....

2014-03-03 00:20:29

BASEL, Switzerland, March 3, 2014 /PRNewswire/ -- -- ELATUS((TM)) fungicide receives regulatory approval in Brazil -- Delivers outstanding control of soybean rust disease -- Higher and more predictable yields for Latin American growers Syngenta today announced that ELATUS, a breakthrough foliar fungicide, has been approved by the Brazilian authorities. ELATUS is a combination of Syngenta's new SDHI chemistry SOLATENOL((TM) )and AMISTAR(®). It offers unrivaled performance...

2014-02-27 12:27:41

LONDON, Feb. 27, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Global Parkinson's Disease Market 2012-2016 TechNavio's analysts forecast the Global Parkinson's Disease market to grow at a CAGR of 1.67 percent over the period 2012-2016. One of the key factors contributing to this market growth is the rise in the aging population. The Global Parkinson's Disease market has also been witnessing the transition toward using drugs that have new...

2014-02-26 08:28:23

DORVAL QC, Feb. 26, 2014 /CNW/ - Novartis announced today that Bexsero(®) (Multicomponent Meningococcal B Vaccine [recombinant, adsorbed]) is now available to doctors and pharmacists across Canada. The vaccine is approved for use in individuals from two months through 17 years of age in Canada. Infants, toddlers and adolescents are at the greatest risk of meningococcal serogroup B (MenB) infection.(1) Bexsero(®) is the first broad-coverage vaccine to help protect against MenB...

2014-02-24 08:29:46

SAN DIEGO, Feb. 24, 2014 /PRNewswire/ -- Thesan Pharmaceuticals announced today the closing of a $49M Series B financing, led by Novo Ventures (a current Investor), with SV Life Sciences and Lundbeckfond Ventures joining Novartis Venture Fund in the syndicate. Thesan's mission is the development of novel approaches for the treatment of dermatological disorders, including acne and atopic dermatitis. "Our focus remains the development of new chemical entities with novel mechanisms of...